EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share (EDAP)

, April 16, 2026 (GLOBE NEWSWIRE) -- EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026

EDAP to Present at Oppenheimer 36th Annual Healthcare MedTech & Services Conference

EDAP to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026

        

EDAP Announces Preliminary Record Fourth Quarter and Full Year 2025 HIFU Revenue; Issues 2026 Revenue Guidance

EDAP Receives FDA 510(k) Clearance for Latest Evolution of Focal One Robotic HIFU 

EDAP to Present at Piper Sandler 37th Annual Healthcare Conference

EDAP Reports Third Quarter 2025 Financial Results

EDAP to Present at Jefferies Global Healthcare Conference in London

 EDAP to Participate in the UBS Global Healthcare Conference

EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025

        

Focal One® Prostate Cancer Awareness Month Campaign Shines Spotlight on Robotic HIFU Treatment Option

         

AUSTIN, Texas, September 8, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today that the French Ministry of Health has awarded reimbursement for High Intensity Focused Ultrasound (HIFU) procedure for the treatment of prostate cancer in France. Reimbursement in France will specifically cover use of the Focal One Robotic HIFU procedure for eligible patients as a primary treatment of localized prostate cancer as well as a salvage treatment option following radiotherapy.

 Company to Host Conference Call and Webcast Today, August 28th, at 8:30 a.m. EDT

Funding to Support Continued Growth of Focal One® Robotic HIFU

AUSTIN, Texas, August 25, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to participate in a fireside chat and host 1x1 investor meetings at the H.C. Wainwright 27th Annual Global Investment Conference, which is being held September 8-10, 2025, in New York City.

Company to host conference call and webcast on Thursday, August 28th at 8:30am EDT

Transition to U.S. reporting status to take effect on January 1, 2026

AUSTIN, Texas, May 27, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the Jefferies Global Healthcare Conference, which is being held June 3-5, 2025, in New York City. 

         

Company to host conference call and webcast on Thursday, May 15th at 8:30am EDT

AUSTIN, Texas, April 29, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced the positive final results of the Focal Ablation Versus Radical Prostatectomy (FARP) Study, the first randomized controlled trial completed comparing ultrasound energy-based focal ablation versus Robotic Prostatectomy. The study achieved its primary endpoint and demonstrated that the rate of treatment failure in the Focal Ablation (FA) group is non-inferior to that in the Radical Prostatectomy (RP) group at the final 36-month follow-up.